List view / Grid view
SK bioscience and IVI convened in consultative meeting to discuss cooperation for next pandemic and announced KRW3 billion donation to IVI to support advancement of global vaccine R&D
Australian researchers have tested a new nasal vaccine in mice, with the potential enhance protection against COVID-19.
A study has suggested that a new vaccine could prevent fentanyl from entering the brain, after showing success in rats.
NIH researchers who intravenously delivered a cancer vaccine to mice report that it increased the number of T cells able to combat tumours.
Researchers show how monkeypox mutations cause virus to replicate, spread faster.
An experimental HIV vaccine, delivered as increasing doses over several days, led to long-lasting and diverse antibody production in monkeys.
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
Scripps scientists have mapped the protein structure of the Hepatitis C virus, paving the way for an effective vaccine.
Researchers from the University of Illinois at Urbana-Champaign found the evolutionary potential of influenza A virus haemagglutinin is extremely restricted by epistatic interactions with neuraminidase.
Texas Biomed and The Access to Advanced Health Institute have been granted $3.5 million to initiate tuberculosis vaccine research, which includes using genetically diverse animal models.
A Boston University researcher has been granted funding for the development pre-clinical models to test potential Nipah virus vaccines.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
Researchers in the US have developed a potential HIV vaccine approach that aims to prompt the creation of broadly neutralising antibodies via mRNA.
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
